BSE filing, NSE: ZYDUSLIFE. Summary written from the filing by ALFA Finder's alert engine.
Zydus Lifesciences Ltd: key numbers
- Share price
- ₹1,175.50
- Market cap
- ₹1,18,283 Cr
- Revenue (annual)
- ₹27,148 Cr
- Net profit (annual)
- ₹5,040 Cr
- P/E (TTM)
- 26.2×Sector 46.5×
- Promoter holding
- 75.01%+0.00% QoQ
- FII holding
- 7.05%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Zydus Lifesciences Ltd
All →Zydus Lifesciences Partnership
Zydus Lifesciences' division Zylidac Bio partnered with Prolific Machines to scale their next-generation biologics manufacturing platform for GMP production.
Zydus Lifesciences Regulatory Approval
Zydus Lifesciences received USFDA approval for its Estradiol-Levonorgestrel Transdermal System ANDA, designated as a CGT. The product is eligible for 180-day exclusivity upon first commercial marketing.
Zydus Lifesciences Board Meeting Date
Zydus Lifesciences intimated a board meeting on 4 Nov 2026 to approve unaudited Q1/H1 FY27 results. Trading window remains closed until 6 Nov 2026.
Zydus Lifesciences Other Announcement
Zydus Lifesciences Limited has been assigned an ESG rating of 71 by NSRAL for the financial year 2026. This unsolicited rating reflects the company's sustainability performance.
Zydus Lifesciences Capacity Expansion: ₹190 Cr Investment
Zydus' JV with Sunshine Healthcare signed a BOI agreement to establish a pharma plant in Sri Lanka. Investment exceeds USD 20 million (~₹190 Cr), targeting 2028.
- Value
- ₹190.0 Cr
Zydus Lifesciences Business Update
Zydus Lifesciences presented post-hoc analysis from its EPICS-III clinical trial for Saroglitazar at ACG 2026. The drug remains under regulatory review for PBC treatment.
Other business update announcements
All →Cybele Industries Business Update
Cybele Industries disclosed joint venture discussions with a third party, still at an initial stage. No agreement has been executed and no value is stated.
Dr. Reddy's Laboratories Business Update
Dr Reddy's says USFDA closed its PAI and GMP inspection at Srikakulam FTO-SEZ Process Unit-02 with VAI classification. The outcome is closed with no monetary penalty.
Vascon Engineers Business Update
Vascon Engineers awarded Neobridge Realty LLP a Rs.72 Crore shell and core work contract over 25 months. The contract is excluding GST and is described as ordinary course of business.
- Value
- ₹72.00 Cr
- Execution
- 25 months
Meesho Business Update
Meesho's Q2 FY27 shareholders' letter reports NMV up 23% YoY to ₹12,911 crore. Festive timing moved the Mega Blockbuster Sale into Q3.
Dhruv Consultancy Services Business Update
Dhruv Consultancy received an empanelment letter of intent for DPR work for Chhattisgarh government departments, valid for 36 months. No contract value or allotted work was disclosed.
- Execution
- 36 months
Peshwa Wheat Business Update
Peshwa Wheat reported unaudited half-year revenue of about Rs.129 Cr for September 2026, up from Rs.109 Cr. The company attributes growth to core wheat processing and by-product utilisation.
- Value
- ₹129.0 Cr